Atlas Venture Life Science Advisors, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001917529
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 8 positions · Total reported value $865.15M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 55.6% · 2 new · 3 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -11.8% · vs SPY -13.9% · Prev Value $881.29M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +13.7% · vs SPY +11.5% · Latest Value $631.19M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, Atlas Venture Life Science Advisors, LLC disclosed 8 equity positions with a combined reported value of $865.15M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were KYMR ($362.58M), DYN ($178.59M), SION ($123.24M). By sector, the heaviest allocations are Health Care 92.5%, Other 7.5%. Versus the prior quarter, allocation shifted toward Other (+0.8pp) and away from Health Care (-0.8pp).
Versus the prior quarter, Atlas Venture Life Science Advisors, LLC opened 2 new positions, trimmed 3 and fully exited 0, a turnover rate of 55.6% of positions. The portfolio's overlap with the prior quarter was 89% of names.
Of the 1 positions fully exited versus the prior quarter, the largest were IMA ($3.08M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
No new positions this quarter.
Fully Exited (vs previous quarter)
- IMA IMAGENEBIO INC · prev qtr: $3.08M
Insider Transactions (Form 4)
Latest Atlas Venture Life Science Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Atlas Venture Life Science Advisors, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $881.29M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 7 positions · $881.29M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: KYMR (KYMERA THERAPEUTICS INC) at 37.1%
- Average position size: $125.90M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new, 1 added, 3 reduced
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.66M | $362.58M | 41.91% | Reduce | |
| 2 |
|
9.13M | $178.59M | 20.64% | Hold | |
| 3 |
|
3.00M | $123.24M | 14.24% | Reduce | |
| 4 |
|
1.51M | $120.22M | 13.89% | Reduce | |
| 5 |
|
6.41M | $59.77M | 6.91% | Hold | |
| 6 |
|
1.14M | $9.11M | 1.05% | Hold | |
| 7 |
|
2.09M | $6.95M | 0.80% | Hold | |
| 8 |
|
827.95K | $4.70M | 0.54% | Hold |
FAQ
What did Atlas Venture Life Science Advisors, LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, Atlas Venture Life Science Advisors, LLC reported 8 equity positions worth $865.15M in aggregate; its largest disclosed positions were KYMR ($362.58M), DYN ($178.59M), SION ($123.24M).
How large is Atlas Venture Life Science Advisors, LLC's portfolio?
Atlas Venture Life Science Advisors, LLC reported $865.15M of long equity holdings across 8 positions as of 2025-Q4. Top-10 holdings account for 100.0% of reported value.
What is Atlas Venture Life Science Advisors, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.